Clay Siegall came to the fight against cancer based on personal experience. When Dr. Siegall was only 19 years old, his father was diagnosed with the disease. Over the next five years, Dr. Siegall observed cancer slowly take his father’s life. There wasn’t much that could be done to treat Dr. Siegall’s father. This is one of the reasons that Clay Siegall became devoted to working to provide solutions and treatments for cancer patients and their families.
Clay Siegall began his education at the University of Maryland where he received a bachelor’s of science degree in the field of zoology. From there, he went on to study at George Washington University receiving a Ph.D in genetics.
After receiving his doctorate, Clay Siegall went to work for the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. Dr. Siegall credits his time working at Bristol-Myers Squibb with teaching him how to run a company. While at that company, he also began working in the area of targeted therapies. These are specialized treatments that utilize information from an individual’s unique genetic makeup. An individualized treatment can be developed for a patient.
In 1998, Dr. Siegall went on to co-found Seattle Genetics. He currently serves as the CEO and Chairman of the Board of this company. This firm develops antibody-drug conjugates to fight cancer. The primary drug that the company has developed is sold under the brand name of Adcetris. This has been a successful drug for the company, and Seattle Genetics is currently developing a number of other drugs in this same class of medication.
Over the course of his career, Clay Siegall has learned that one of the most important things that a person can do is to learn as much as possible from every person that one is associated with. A person needs to find smart people to associate with and interact with them on a regular basis.
Clay Siegall believes in the power of collaboration. His company works with other major drug developers in order to bring about major new treatments in the battle against cancer.